Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications
Journal of Clinical Medicine · 19.10.2024 · 13 (20) · 6254
DOI: 10.3390/jcm13206254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.10.2024. Verfasst von Nida Alsaffar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Sciences, Mohammed Al-Mana College for Medical Sciences, Al Safa, Dammam 34222, Saudi Arabia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Northern Border University, Arar, KSA.
Abstract (Originalsprache)
Background and Objectives: Hydroxyurea (HU) is an effective medication used to reduce the frequency of painful crises associated with sickle cell disease (SCD). However, data describing its prevalence among SCD patients in the Eastern Region of Saudi Arabia are scarce. This is a multi-center, retrospective, cross-sectional study that aims to investigate the pattern of prescribing HU in SCD patients and to determine the association between prescribing HU and other co-prescribed medications used to manage SCD complications.
Methods
Data were collected from patients who visited the hematology clinics of Al-Qatif Central Hospital (QCH) and King Fahad Hospital in Hofuf (KFHH) between June 2021 to May 2023. The data included demographics, prescribed medications, and recent laboratory test results, all of which were collected from patients’ medical records. Descriptive statistics were utilized to assess the difference between HU users vs. non-users. A binary logistic regression model was used to determine the association between prescribing HU and co-prescribed medications used to manage SCD complications. The results are presented as the odds ratio (OR) and 95% confidence interval (95% CI).
Results
This study included 2816 SCD patients with a 56% prevalence of HU prescription. HU was prescribed for young age groups more often compared to old age group patients. Young males were more likely to be prescribed with HU compared to females, and it becomes dominant in females after the age of 36. HU users were more likely to have paracetamol (69% vs. 53%, OR = 1.9, 95% CI 1.6–2.2), NSAIDs (50% vs. 35%, OR = 1.7, 95% CI 1.5–2), and opioids (41% vs. 37%, OR = 1.3, 95% CI 1.1–1.6) co-prescribed, and less often to have laxatives (8% vs. 5%, OR = 0.66, 95% CI 0.48–0.9) and anticoagulants (22% vs. 15%, OR = 0.56, 95% CI 0.46–0.68) co-prescribed compared to non-users.
Conclusions
The pattern of prescribing HU, supported by the association findings, raises concerns about patients’ compliance and adherence to HU therapy. Early health education, specifically to young female SCD patients, is warranted to increase the success rate of HU therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Laboratory Sciences, Mohammed Al-Mana College for Medical Sciences, Al Safa, Dammam 34222, Saudi Arabia.
- Blood and Cancer Research Department, King Abdullah International Medical Research Centre (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Ministry of National Guard-Health Affairs (MNG-HA), R…
- Department of Respiratory Therapy, Mohammed Al-Mana College for Medical Sciences, Dammam 34222, Saudi Arabia.
- Department of Diagnostic Laboratory, King Fahad Hospital Hofuf, Ministry of Health, Al Hofuf 36441, Saudi Arabia.
- Department of Diagnostic Laboratory, Maternity and Children Hospital, Ministry of Health, Al Mubarraz 36422, Saudi Arabia.
- Department of Clinical Practice, Faculty of Pharmacy, Northern Border University, Rafha 91911, Saudi Arabia.
ORCID-Profile: Nida Alsaffar, Mohammed Ali Alsaleh, Abdulmonem Ali Alsaleh, Mohammad Hussain Al Khamees
Förderung
- Deanship of Scientific Research at Northern Border University, Arar, KSA
Zitieren
APA
Alsaffar, N., Alsaleh, M. A., Alsaleh, A. A., Ghanem, N. Z., Al Khamees, M. H., Alqurain, M. A., Almatouq, J., AlAlwan, B., & Alqurain, A. A. (2024). Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications. Journal of Clinical Medicine, 13(20), 6254. https://doi.org/10.3390/jcm13206254
Vancouver
Alsaffar N, Alsaleh MA, Alsaleh AA, Ghanem NZ, Al Khamees MH, Alqurain MA, et al. Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications. Journal of Clinical Medicine. 2024;13(20):6254. doi:10.3390/jcm13206254
BibTeX
@article{Alsaffar2024,
author = {Alsaffar, Nida and Alsaleh, Mohammed Ali and Alsaleh, Abdulmonem Ali and Ghanem, Neda Z and Al Khamees, Mohammad Hussain and Alqurain, Mohammed A and Almatouq, Jenan and AlAlwan, Bader and Alqurain, Aymen A},
title = {Prescribing Hydroxyurea in Sickle Cell Disease Patients: The Pattern and Association with Co-Prescribed Medications Used to Manage the Disease Complications},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {20},
pages = {6254},
doi = {10.3390/jcm13206254}
}
EUVIMED